Intramuscular, SubcutaneousActive immunisation against poliomyelitisAdult: As inactivated trivalent vaccine of polio virus types 1, 2, 3: For unvaccinated or inadequately vaccinated patients at increased risk of exposure: Primary immunisation: 3 doses of 0.5 mL, given via IM or SC inj at intervals of 4-8 weeks. Booster dose: 0.5 mL as a single dose every 10 years in patients exposed to a continuing risk of infection. Recommendations may vary between countries and use must be in accordance with local immunisation guidelines.
Child: As trivalent inactivated vaccine of polio virus types 1, 2, 3: Primary immunisation: 3 doses of 0.5 mL, given at intervals of 4-8 weeks. Booster dose: 0.5 mL, given at 4-6 years of age. All doses may be administered via IM or SC inj into the mid-lateral aspect of the thigh (for infants and small children) or deltoid area (for older children and adolescents). Recommendations may vary between countries and use must be in accordance with local immunisation guidelines.
|
|
|
Hypersensitivity. Acute febrile illness.
|
Patient with hypersensitivity to neomycin, polymyxin B, or streptomycin; bleeding disorder, thrombocytopenia. Postpone immunisation in patients with acute febrile illness and during periods of severe immunosuppression (e.g. patients receiving chemotherapy, radiation therapy, or other immunosuppressive treatment [including high-dose corticosteroids]), if appropriate. Children. Pregnancy and lactation.
|
Significant: Hypersensitivity or anaphylactoid reactions, shoulder injury associated with vaccine administration (e.g. bursitis or tendinopathy), bleeding or haematoma (IM), syncope.
Blood and lymphatic system disorders: Lymphadenopathy.
Gastrointestinal disorders: Vomiting.
General disorders and administration site conditions: Fever, inj site reactions (e.g. pain, swelling, redness, tenderness).
Metabolism and nutrition disorders: Anorexia.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Drowsiness, headache, convulsions, transient and mild paraesthesia of the limbs.
Psychiatric disorders: Irritability, agitation.
Skin and subcutaneous tissue disorders: Rash, urticaria.
|
IM/Parenteral/SC: Z (Has not been associated with adverse pregnancy outcomes. May be given when there is risk of exposure. Consult product literature and clinical guidelines for specific recommendations.)
|
Monitor for signs and symptoms of syncope and hypersensitivity reactions within 15 minutes after administration.
|
Increased risk of bleeding with anticoagulants. Diminished therapeutic effect with systemic corticosteroids and immunosuppressants.
|
Description:
Mechanism of Action: Poliomyelitis vaccine contains 3 strains of inactivated poliovirus types 1, 2, and 3. It provides active immunity by inducing the production of antibodies against poliovirus infections.
Synonym(s): Salk vaccine.
|
Store between 2-8°C. Do not freeze. Protect from light.
|
|
|
J07BF03 - poliomyelitis, trivalent, inactivated, whole virus ; Belongs to the class of poliomyelitis viral vaccines.
|
Anon. Poliovirus Vaccine Inactivated. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 02/10/2024. Brayfield A, Cadart C (eds). Poliomyelitis Vaccine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/10/2024. Ipol Injection, Suspension (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 02/10/2024. Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics. Ipol 0.5 mL Suspension for Injection data sheet 31 January 2024. Medsafe. http://www.medsafe.govt.nz. Accessed 02/10/2024. Poliovirus Vaccine (Inactivated). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 02/10/2024. Poliovirus Vaccine, Inactivated, IPV. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 02/10/2024.
|
Sign Out
Continue with Google